Sage Journals: Discover world-class research

Abstract

The KORUS FTA includes various clauses on marketing approval of new medicines and their reimbursement decisions. We aim to capture the availability of new medicines, to measure drug lags for new medicines, and to demonstrate the effect of the KORUS FTA on the timely availability of new medicines in the Korean market. We selected new drug applications approved in the United States between 2007 and 2015, calculated the drug lag, which was defined as the time difference between the date of regulatory approval in the United States and in Korea, and constructed a logistic and Cox model to capture the effect of the variables of interest on the availability and drug lag of new medicines in the Korean market. The FDA in the United States approved 160 NDAs between 2007 and 2015. The KORUS FTA does not increase the availability of new medicines or shorten the drug lag of new medicines. However, the presence of the manufacturer in Korea was significantly related to the availability and drug lag in the Korean market. It is noteworthy that the presence of the manufacturer, which is a kind of by-product of free trade in pharmaceuticals, affected drug lag.

Keywords

free trade agreement drug lag access to medicines South Korea KORUS FTA

Get full access to this article

View all access options for this article.

References

World Health Organization. Improving Access to Medicines in the South-East Asia Region: Progress, Challenges, Priorities. Geneva, Switzerland: World Health Organization; 2017.

Son

K-B.

Understanding the adoption of new drugs decided by several stakeholders in the South Korean market: a nonparametric event history analysis. Health Econ Rev. 2018; 8(1):31.

Ades

Senterre

Zardavas

, et al. An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case. Eur J Cancer. 2014; 50(18):3089–3097.

Garattini

Cornago

De Compadri

Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis. Health Policy. 2007; 82(3):330–339.

Wileman

Mishra

Drug lag and key regulatory barriers in the emerging markets. Perspect Clin Res. 2010; 1(2):51.

Stevens

Milne

Health technology assessment in England and Wales. Int J Technol Assess Health Care. 2004; 20(1):11–24.

Garrido

Kristensen

Busse

Nielsen

Health Technology Assessment and Health Policy-Making in Europe: Current Status, Challenges and Potential. Copenhagen, Denmark: WHO Regional Office Europe; 2008.

Bae

E-Y

Hong

J-M

Kwon

H-Y

, et al. Eight-year experience of using HTA in drug reimbursement: South Korea. Health Policy. 2016; 120(6):612–620.

Kessler

Hass

Feiden

Lumpkin

Temple

Approval of new drugs in the United States: comparison with the United Kingdom, Germany, and Japan. JAMA. 1996; 276(22):1826–1831.

10.

Wardell

WM.

Introduction of new therapeutic drugs in the United States and Great Britain: an international comparison. Clin Pharmacol Therap. 1973; 14(5):773–790.

11.

Wardell

WM.

The drug lag revisited: comparison by therapeutic area of patterns of drugs marketed in the United States and Great Britain from 1972 through 1976. Clin Pharmacol Therap. 1978; 24(5):499–524.

12.

Kaitin

Brown

JS.

A drug lag update. Drug Inf J. 1995; 29(2):361–373.

13.

Andersson

The drug lag issue: the debate seen from an international perspective. Int J Health Serv. 1992; 22(1):53–72.

14.

Kaitin

Mattison

Northington

Lasagna

The drug lag: an update of new drug introductions in the United States and in the United Kingdom, 1977 through 1987. Clin Pharmacol Therap. 1989; 46(2):121–138.

15.

Rawson

NS.

Comparison of numbers and timing of new medication regulatory approvals in Canada and New Zealand. Regulat Toxicol Pharmacol. 2019; 101:24–28.

16.

Tsuji

Tsutani

Approval of new drugs 1999–2007: comparison of the US, the EU and Japan situations. J Clin Pharm Therap. 2010; 35(3):289–301.

17.

Yonemori

Hirakawa

Ando

, et al. The notorious “drug lag” for oncology drugs in Japan. Investigation New Drugs. 2011; 29(4):706–712.

18.

Yang

B-M

Bae

E-Y

Kim

Economic evaluation and pharmaceutical reimbursement reform in South Korea’s National Health Insurance. Health Affairs. 2008; 27(1):179–187.

19.

Korea Health Industry Development Institute. Pharmaceutical Industry Analysis Report. Chungbuk, South Korea: Korea Health Industry Development Institute; 2017.

20.

Son

K-B

Lee

T-J.

The trends and constructive ambiguity in international agreements on intellectual property and pharmaceutical affairs: implications for domestic legislations in low-and middle-income countries. Glob Public Health. 2018; 13(9):1169–1178.

21.

Republic of Korea Ministry of Trade Industry and Energy. Korea United States Free Trade Agreement. http://www.fta.go.kr/us/doc/1/. Accessed December 18, 2019.

22.

Son

K-B

Lopert

Gleeson

Lee

T-J.

Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States.

Glob Health. 2018; 14(1):101.

23.

U.S. Food and Drug Administration. Drugs@FDA Glossary of Terms. https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-glossary-terms#N. Published 2019. Accessed December 18, 2019.

24.

The US Food and Drug Administration. Priority Review. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review. Published 2019. Accessed 14 October, 2019.

25.

Center for Innovation in Regulatory Science. New Drug Approvals in Six Major Authorities 2008-2017. London, England: Center for Innovation in Regulatory Science; 2018.

26.

Ministry of Food and Drug Safety. Guide to Drug Approval System in Korea. Osong, South Korea: Ministry of Food and Drug Safety; 2017.

27.

Maeda

Kurokawa

Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan?

Int J Clin Oncol. 2015; 20(6):1072–1080.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.04 MB

Do Free Trade Agreements Matter to Drug Lag? Recent Evidence From Korea After the Korea–U.S. Free Trade Agreement

Abstract

Keywords

Get full access to this article

References

Supplementary Material